Architectural (type IA) focal cortical dysplasia and parvalbumin immunostaining in temporal lobe epilepsy

Rita Garbelli, Alessandra Meroni, Giuseppina Magnaghi, Maria Sana Beolchi, Arianna Ferrario, Laura Tassi, Manuela Bramerio, Roberto Spreafico

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose: We analyzed 26 surgically treated patients operated on for intractable epilepsy associated with type IA (architectural) cortical dysplasia, to investigate neuropathologic and immunocytochemical features, particularly of the γ-aminobutyric acid (GABA)ergic system, and to compare the findings with those observed in normal cortex. Methods:. Routinely stained slides and serial sections immunostained for neurofilaments (SMI 311), microtubule- associated protein-2 (MAP-2), neuron-specific nuclear protein (NeuN), glial fibrillary acidic protein (GFAP), parvalbumin (PV), calbindin (CB), and calretinin (CR) were processed. Some sections were processed by using single-immunoperoxidase procedures; others were processed for double immunofluorescence labelling and observed by confocal microscopy. The density of inhibitory PV-immunoreactive interneurons was quantitatively assessed in all patients and control cases by using a two-dimensional cell-counting technique on PV immunostained sections. Results: The density of PV-immunoreactive interneurons was significantly reduced in this group of patients, whereas CB- and CR- positivity appeared similar to those in normal cortex. In five cases, architectural abnormalities, in addition to those that defined type 1A dysplasia, were present and characterized by abnormal clusters of neurons and laminar cellular loss in superficial cortical laminate. Conclusions: The reduction of PV expression in type IA cortical dysplasia suggests an impairment of the GABAergic system as a possible mechanism for the epileptogenicity; in addition, PV immunoreactivity can be helpful in the neuropathologic characterization of this form of cortical dysplasia.

Original languageEnglish
Pages (from-to)1074-1078
Number of pages5
JournalEpilepsia
Volume47
Issue number6
DOIs
Publication statusPublished - Jun 2006

Fingerprint

Malformations of Cortical Development
Parvalbumins
Temporal Lobe Epilepsy
Calbindin 2
Calbindins
Interneurons
Aminobutyrates
Neurons
Microtubule-Associated Proteins
Intermediate Filaments
Glial Fibrillary Acidic Protein
Nuclear Proteins
Confocal Microscopy
gamma-Aminobutyric Acid
Fluorescent Antibody Technique

Keywords

  • Immunocytochemistry
  • Parvalbumin
  • Temporal lobe epilepsy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Garbelli, R., Meroni, A., Magnaghi, G., Beolchi, M. S., Ferrario, A., Tassi, L., ... Spreafico, R. (2006). Architectural (type IA) focal cortical dysplasia and parvalbumin immunostaining in temporal lobe epilepsy. Epilepsia, 47(6), 1074-1078. https://doi.org/10.1111/j.1528-1167.2006.00577.x

Architectural (type IA) focal cortical dysplasia and parvalbumin immunostaining in temporal lobe epilepsy. / Garbelli, Rita; Meroni, Alessandra; Magnaghi, Giuseppina; Beolchi, Maria Sana; Ferrario, Arianna; Tassi, Laura; Bramerio, Manuela; Spreafico, Roberto.

In: Epilepsia, Vol. 47, No. 6, 06.2006, p. 1074-1078.

Research output: Contribution to journalArticle

Garbelli, R, Meroni, A, Magnaghi, G, Beolchi, MS, Ferrario, A, Tassi, L, Bramerio, M & Spreafico, R 2006, 'Architectural (type IA) focal cortical dysplasia and parvalbumin immunostaining in temporal lobe epilepsy', Epilepsia, vol. 47, no. 6, pp. 1074-1078. https://doi.org/10.1111/j.1528-1167.2006.00577.x
Garbelli, Rita ; Meroni, Alessandra ; Magnaghi, Giuseppina ; Beolchi, Maria Sana ; Ferrario, Arianna ; Tassi, Laura ; Bramerio, Manuela ; Spreafico, Roberto. / Architectural (type IA) focal cortical dysplasia and parvalbumin immunostaining in temporal lobe epilepsy. In: Epilepsia. 2006 ; Vol. 47, No. 6. pp. 1074-1078.
@article{13f62feaf5ea4276b3665d85a5d15820,
title = "Architectural (type IA) focal cortical dysplasia and parvalbumin immunostaining in temporal lobe epilepsy",
abstract = "Purpose: We analyzed 26 surgically treated patients operated on for intractable epilepsy associated with type IA (architectural) cortical dysplasia, to investigate neuropathologic and immunocytochemical features, particularly of the γ-aminobutyric acid (GABA)ergic system, and to compare the findings with those observed in normal cortex. Methods:. Routinely stained slides and serial sections immunostained for neurofilaments (SMI 311), microtubule- associated protein-2 (MAP-2), neuron-specific nuclear protein (NeuN), glial fibrillary acidic protein (GFAP), parvalbumin (PV), calbindin (CB), and calretinin (CR) were processed. Some sections were processed by using single-immunoperoxidase procedures; others were processed for double immunofluorescence labelling and observed by confocal microscopy. The density of inhibitory PV-immunoreactive interneurons was quantitatively assessed in all patients and control cases by using a two-dimensional cell-counting technique on PV immunostained sections. Results: The density of PV-immunoreactive interneurons was significantly reduced in this group of patients, whereas CB- and CR- positivity appeared similar to those in normal cortex. In five cases, architectural abnormalities, in addition to those that defined type 1A dysplasia, were present and characterized by abnormal clusters of neurons and laminar cellular loss in superficial cortical laminate. Conclusions: The reduction of PV expression in type IA cortical dysplasia suggests an impairment of the GABAergic system as a possible mechanism for the epileptogenicity; in addition, PV immunoreactivity can be helpful in the neuropathologic characterization of this form of cortical dysplasia.",
keywords = "Immunocytochemistry, Parvalbumin, Temporal lobe epilepsy",
author = "Rita Garbelli and Alessandra Meroni and Giuseppina Magnaghi and Beolchi, {Maria Sana} and Arianna Ferrario and Laura Tassi and Manuela Bramerio and Roberto Spreafico",
year = "2006",
month = "6",
doi = "10.1111/j.1528-1167.2006.00577.x",
language = "English",
volume = "47",
pages = "1074--1078",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Blackwell Publishing Inc.",
number = "6",

}

TY - JOUR

T1 - Architectural (type IA) focal cortical dysplasia and parvalbumin immunostaining in temporal lobe epilepsy

AU - Garbelli, Rita

AU - Meroni, Alessandra

AU - Magnaghi, Giuseppina

AU - Beolchi, Maria Sana

AU - Ferrario, Arianna

AU - Tassi, Laura

AU - Bramerio, Manuela

AU - Spreafico, Roberto

PY - 2006/6

Y1 - 2006/6

N2 - Purpose: We analyzed 26 surgically treated patients operated on for intractable epilepsy associated with type IA (architectural) cortical dysplasia, to investigate neuropathologic and immunocytochemical features, particularly of the γ-aminobutyric acid (GABA)ergic system, and to compare the findings with those observed in normal cortex. Methods:. Routinely stained slides and serial sections immunostained for neurofilaments (SMI 311), microtubule- associated protein-2 (MAP-2), neuron-specific nuclear protein (NeuN), glial fibrillary acidic protein (GFAP), parvalbumin (PV), calbindin (CB), and calretinin (CR) were processed. Some sections were processed by using single-immunoperoxidase procedures; others were processed for double immunofluorescence labelling and observed by confocal microscopy. The density of inhibitory PV-immunoreactive interneurons was quantitatively assessed in all patients and control cases by using a two-dimensional cell-counting technique on PV immunostained sections. Results: The density of PV-immunoreactive interneurons was significantly reduced in this group of patients, whereas CB- and CR- positivity appeared similar to those in normal cortex. In five cases, architectural abnormalities, in addition to those that defined type 1A dysplasia, were present and characterized by abnormal clusters of neurons and laminar cellular loss in superficial cortical laminate. Conclusions: The reduction of PV expression in type IA cortical dysplasia suggests an impairment of the GABAergic system as a possible mechanism for the epileptogenicity; in addition, PV immunoreactivity can be helpful in the neuropathologic characterization of this form of cortical dysplasia.

AB - Purpose: We analyzed 26 surgically treated patients operated on for intractable epilepsy associated with type IA (architectural) cortical dysplasia, to investigate neuropathologic and immunocytochemical features, particularly of the γ-aminobutyric acid (GABA)ergic system, and to compare the findings with those observed in normal cortex. Methods:. Routinely stained slides and serial sections immunostained for neurofilaments (SMI 311), microtubule- associated protein-2 (MAP-2), neuron-specific nuclear protein (NeuN), glial fibrillary acidic protein (GFAP), parvalbumin (PV), calbindin (CB), and calretinin (CR) were processed. Some sections were processed by using single-immunoperoxidase procedures; others were processed for double immunofluorescence labelling and observed by confocal microscopy. The density of inhibitory PV-immunoreactive interneurons was quantitatively assessed in all patients and control cases by using a two-dimensional cell-counting technique on PV immunostained sections. Results: The density of PV-immunoreactive interneurons was significantly reduced in this group of patients, whereas CB- and CR- positivity appeared similar to those in normal cortex. In five cases, architectural abnormalities, in addition to those that defined type 1A dysplasia, were present and characterized by abnormal clusters of neurons and laminar cellular loss in superficial cortical laminate. Conclusions: The reduction of PV expression in type IA cortical dysplasia suggests an impairment of the GABAergic system as a possible mechanism for the epileptogenicity; in addition, PV immunoreactivity can be helpful in the neuropathologic characterization of this form of cortical dysplasia.

KW - Immunocytochemistry

KW - Parvalbumin

KW - Temporal lobe epilepsy

UR - http://www.scopus.com/inward/record.url?scp=33744501006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744501006&partnerID=8YFLogxK

U2 - 10.1111/j.1528-1167.2006.00577.x

DO - 10.1111/j.1528-1167.2006.00577.x

M3 - Article

C2 - 16822257

AN - SCOPUS:33744501006

VL - 47

SP - 1074

EP - 1078

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 6

ER -